- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07487818
En undersøgelse af vagusnervestimulation i forbindelse med NRT til rygningophør
Brug af vagusnervestimulering i kombination med NRT til rygestop
The purpose of this study is to provide preliminary evidence for the efficacy of 12 weeks of vagal nerve stimulation (VNS) and nicotine replacement therapy (NRT) for increasing smoking abstinence rates.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This study will evaluate the role of vagal nerve stimulation as a potential adjunct to nicotine patches to help smokers stop smoking.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Sara Seegmiller, M.A.N, R.N
- Telefonnummer: 507-538-7820
- E-mail: NicotineRes@mayo.edu
Undersøgelse Kontakt Backup
- Navn: Donna K Lawson
- Telefonnummer: 507-255-7975
- E-mail: NicontineRes@mayo.edu
Studiesteder
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic in Rochester
-
Ledende efterforsker:
- Ivana T Croghan, PhD
-
Ledende efterforsker:
- Ryan T Hurt, MD, PhD
-
Kontakt:
- Shawn Fokken, CCRP
- Telefonnummer: 507-538-7820
- E-mail: RSTGIMRESStudies@mayo.edu
-
Kontakt:
- Sara Seegmiller, RN
- Telefonnummer: 507-538-7820
- E-mail: RSTGIMRESStudies@mayo.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 years of age or older at the time of consent.
- Currently smoking cigarettes on a regular basis
- Motivated to stop smoking (on a scale of 0 to 10, motivation must be 3 or above);
- Ability to participate fully in all aspects of the study.
- Have the ability to provide informed consent.
- Have no contraindicating comorbid health conditions that would interfere with study participation, as determined by the clinical investigators.
Exclusion Criteria:
-
Patients with a current moderate/severe depression as assessed by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9).
-
Patients who are or have used an investigational drug within the past 30 days.
-
Patients who are currently using medication(s) known to interact with varenicline.
-
Patients who have clinically significant acute/chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, psychological, respiratory, or metabolic disease.
-
Patients with a known allergy to nicotine patches or varenicline.
-
Patients with a personal history of acute pancreatitis, hypoglycemia, acute kidney injury or impairment of renal function, type 1 diabetes or diabetic ketoacidosis, and/or severe gastrointestinal disease such as gastroparesis.
-
Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device.
-
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
-
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
-
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
-
Patients who have a metallic device such as a stent, bone plate, or bone screw implanted at or near your neck
-
Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).
-
Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded.
- Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine devices, surgical sterilization, and abstinence. The study does not include vulnerable populations.
- Specifically, the study does not include fetuses, neonates, pregnant women, children (<18 years of age), prisoners, institutionalized individuals, or other vulnerable populations.
i. All female participants of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during study participation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Vagal Nerve Stimulator and Nicotine Replacement Patches
This arm will receive nicotine patches (21 mg) for 12 weeks and brief behavioral therapy (through the self-help manual Smoke Free and Living It), as well as the vagal nerve stimulator (VNS) device to use during these 12 weeks while trying to stop smoking. The VNS delivers up to 30 stimulations over 24 hours. |
VNS is a handheld, rechargeable, portable device that delivers electrical signals to the vagal nerve when positioned on the skin of the neck at the appropriate location to stimulate the vagal nerve for 2 minutes at each treatment. During these 12 weeks, participants will also use a 21 mg nicotine patch daily.
Andre navne:
|
|
Aktiv komparator: Nicotine Replacement Patches
This arm will receive nicotine patches (21 mg) for 12 weeks and brief behavioral therapy (through the self-help manual Smoke Free and Living It). |
Use of a 21 mg nicotine patch daily for up to 12 weeks
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Smoking Abstinence
Tidsramme: week 12
|
reporting smoking abstinence and having it be biochemically confirmed (CO reading of < 8 ppm) |
week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Ivana T Croghan, PhD, Mayo Clinic
- Ledende efterforsker: Ryan T Hurt, MD, PhD, Mayo Clinic
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 25-005696
- 1R21CA302802-01 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .